Latest news

Debiopharm’S Pamorelin® Receives Swiss Approval for subcutaneous Administration, Enhancing Treatment Flexibility for Prostate Cancer Patients

Debiopharm Pushes The Boundaries Of Innovation In Antibiotic Development Against Gonorrhea With First-in-human Debio 1453 Trial

Released by Repare Therapeutics: Repare Enters Exclusive Worldwide Licensing Agreement with Debiopharm for Lunresertib

10e Challenge Qualité de vie du patient : cinq projets innovants récompensés, cap vers la finale !

ITM and Debiopharm Announce First Patient Imaged in New Study Arm of Phase 1/2 Trial Evaluating ITM-94 as Diagnostic Agent…

Debiopharm’s ADC Research Gains Momentum with Launch of First-In-Human Trial Assessing Debio 1562m in Acute Myeloid Leukemia Patients

Debiopharm And Alkyon Therapeutics Announce Research Collaboration To Advance The Next Generation Of Radioligand Therapies

Debiopharm Ignites Oncology Innovation with Clinical and Translational Data on Debio 0123 at the 2025 ASCO Annual Meeting in Chicago

Carb-X Grants Debiopharm An Additional $12.3 Million To Advance Development Of Novel Antibiotic Against Gonorrhea